| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| 5g | |||
| Other Sizes |
| Targets |
Clobetasone butyrate targets the glucocorticoid receptor. It acts as an agonist, binding to the receptor and modulating gene expression. By activating the glucocorticoid receptor, it suppresses inflammation, reduces itching, and alleviates redness associated with skin disorders.
|
|---|---|
| ln Vitro |
In vitro, Clobetasone butyrate is a synthetic glucocorticoid with topical anti-inflammatory activity. Its activity can be measured in cell-based assays using immune cells or skin cells. It suppresses the production of inflammatory cytokines and mediators.
|
| ln Vivo |
The application of clobetazone butyrate (0.05%; 7 weeks) topically may result in thinned epidermis. For a period of seven weeks, clobetazone butyrate had a significantly less effect on epidermal thinning in pigs than flunandrolone (0.05%). or 0.025 percent fluocinolone acetonide, both of which thin the skin of pigs. extreme atrophy [1].
In vivo, Clobetasone butyrate is effective in treating corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis. It reduces erythema and itchiness associated with eczema and dermatitis. It is applied topically as a cream or ointment. |
| Enzyme Assay |
Clobetasone butyrate is evaluated in cell-free receptor binding assays to determine its affinity for the glucocorticoid receptor. Radioligand binding displacement assays are performed using membrane preparations expressing the receptor. Competition binding experiments are conducted with increasing concentrations of Clobetasone butyrate and a fixed concentration of a labeled reference ligand.
|
| Cell Assay |
Clobetasone butyrate is assessed in cell-based assays using skin cells or immune cells. Cells are treated with Clobetasone butyrate, and the production of inflammatory cytokines and mediators is measured. Its anti-inflammatory activity is evaluated.
|
| Animal Protocol |
Animal/Disease Models: Large white domestic pig [1]
Doses: 0.5% Skin application administration time: 7 weeks Experimental Results: Caused moderate to mild atrophy. Clobetasone butyrate is applied topically in animal models and in clinical settings to treat skin inflammation. It is used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis. Efficacy is assessed by measuring skin inflammation, erythema, and itching. |
| ADME/Pharmacokinetics |
Clobetasone butyrate has a molecular weight of 478.98 and a molecular formula of C26H36ClFO5. It has a CAS number of 25122-57-0. The compound is a synthetic corticosteroid. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Clobetasone butyrate beyond its known use as a topical corticosteroid. It is generally well-tolerated when used topically. Prolonged use can cause skin atrophy and other side effects. The compound is a therapeutic agent and is available by prescription only.
|
| References | |
| Additional Infomation |
Clobetasone butyrate is an organic molecular entity.
Clobetasone butyrate is also known as SN203, Emovate, and Eumovate. It is a synthetic glucocorticoid. The compound is a therapeutic agent. |
| Molecular Formula |
C26H32CLFO5
|
|---|---|
| Molecular Weight |
478.9854
|
| Exact Mass |
478.192
|
| CAS # |
25122-57-0
|
| Related CAS # |
54063-32-0;25122-57-0 (butyrate);
|
| PubChem CID |
71386
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
573.3±50.0 °C at 760 mmHg
|
| Melting Point |
179 °C
|
| Flash Point |
181.1±19.3 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
4.82
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
987
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(CC(=O)[C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)C)C)C(=O)CCl
|
| InChi Key |
FBRAWBYQGRLCEK-AVVSTMBFSA-N
|
| InChi Code |
InChI=1S/C26H32ClFO5/c1-5-6-22(32)33-26(21(31)14-27)15(2)11-19-18-8-7-16-12-17(29)9-10-23(16,3)25(18,28)20(30)13-24(19,26)4/h9-10,12,15,18-19H,5-8,11,13-14H2,1-4H3/t15-,18-,19-,23-,24-,25-,26-/m0/s1
|
| Chemical Name |
[(8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-yl] butanoate
|
| Synonyms |
SN203 Clobetasone 17-butyrate Clobetasone ButyrateSN203 EmovateSN-203GR 2/1214SN 203EumovateCloptisonMolivate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~521.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (13.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0877 mL | 10.4386 mL | 20.8773 mL | |
| 5 mM | 0.4175 mL | 2.0877 mL | 4.1755 mL | |
| 10 mM | 0.2088 mL | 1.0439 mL | 2.0877 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
